Farewell to TQT studies, new webinar hosted by Xtalks - 13 WTHR Indianapolis

This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.

SOURCE: Xtalks

Xtalks presents an exciting live webinar on Thursday, February 7, 2013 at 11:00am EST on TQT studies. Join keynote speakers Dr. Jay Mason, Chief Medical Officer at Spaulding Clinical Research; Dr. Charles Benson, Medical Fellow with Eli Lilly &Co. and E14 Implementation Working Group Member and Mr. Daniel Selness, of Spaulding Research.

Toronto, Canada (PRWEB) January 24, 2013

As requirements for cardiac studies tighten, the ICH-E14 guideline is essentially mandated for Thorough QT studies.

However, these studies are expensive and are usually performed late in Phase II or in Phase III, after many subjects have been exposed to an undefined repolarization risk. Also, by using the E-14 approach, a Sponsor will not learn of a drug’s QT liability until after a large expenditure of money and personnel effort.

A better assessment of QT liability can be achieved early in the drug development cycle, at lower cost to the Sponsor and lower risk to the subject. The strategy to achieve these goals will be discussed by the experts in this webinar.

For more information about this event or to register, visit: http://xtks.in/xto553-event

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/1/prweb10353974.htm